Complement C3 inhibition restores myasthenia gravis AChR antibody-mediated muscle pathophysiology - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/42247725/
This work was supported by Familjen Erling-Perssons Stiftelse (grant # 2022_0030 to ARP), the Myasthenia Gravis Foundation of America, and the Swedish Research Council (grant # 2025-02779 to ARP). MLF...
Retrospective analysis showed most CIDP patients maintained clinical stability on low-dose IVIg, while successful treatment withdrawal was achievable in many attempted cases, highlighting opportunities for proactive weaning strategies.
Complement C5 inhibition in generalized myasthenia gravis is associated with improved survival and increased cardiovascular risk - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/42220523/
C5 inhibition in generalized MG is associated with improved survival but increased cardiovascular and thromboembolic risk. Although limited by its retrospective design, this analysis highlights a clinically relevant safety signal...
Retrospective cohort study found complement C5 inhibition in generalized myasthenia gravis improved survival but increased cardiovascular, thrombotic, and kidney risks, emphasizing the need for ongoing safety monitoring.
Hsa_circ_0065149 mediates the ceRNA network pathway: Research on the mechanism regulating myasthenia gravis - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/42171932/
CircRNAs have been linked to the pathogenesis and progression of myasthenia gravis (MG), but research on this association remains limited. This study aims to provide a new perspective for understanding...
Molecular study identified hsa_circ_0065149 as a regulator of myasthenia gravis through the miR-330-5p/CHRNA1 ceRNA pathway, potentially contributing to impaired neuromuscular junction acetylcholine receptor signal transmission.
The evolution of CAR therapies across oncology and autoimmunity: mechanistic insights and therapeutic innovations - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/42143506/
Chimeric antigen receptor (CAR)-engineered cellular therapies have progressed from early proof of concept into highly programmable platforms capable of mediating potent cytotoxicity and precise immune modulation. In oncology, successive CAR...
Review examines evolving CAR-based cellular therapies for oncology and autoimmune diseases, highlighting CAR-T, CAAR-T, and CAR-Treg approaches under investigation for immune modulation in myasthenia gravis and related disorders.
Factors associated with initial exacerbation after corticosteroids treatment in myasthenia gravis patients with bulbar symptoms - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/42107209/
IVMP regimen is associated with initial exacerbation after CS treatment in bulbar MG patients. Caution should be exercised when using IVMP regimen in clinical practice for bulbar MG patients, especially...
Retrospective cohort study identified intravenous methylprednisolone, reduced cough strength, and low maximal voluntary ventilation as factors associated with corticosteroid-related exacerbation in bulbar myasthenia gravis patients.